205 related articles for article (PubMed ID: 33269990)
21. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
23. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
[TBL] [Abstract][Full Text] [Related]
24. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
25. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
26. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
29. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
Wondimu A; Postma MJ; van Hulst M
Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
[TBL] [Abstract][Full Text] [Related]
31. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
[TBL] [Abstract][Full Text] [Related]
36. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
37. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
38. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
